Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2020-07-01 / J Immunother Cancer 2020 07;8(2)Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2020-03-16 / Cancer Cell 2020 03;37(3):289-307.e9Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2020-01-01 / Cytotherapy 2020 01;22(1):6-15Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-11-01 / Am J Cancer Res 2019;9(11):2456-2468Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-10-17 / Pathol. Res. Pract. 2019 Dec;215(12):152691A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-08-08 / Front Immunol 2019;10:1832Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-06-19 / Oncology 2019 Jun;:1-14Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15748)Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15783)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives